ArticleESMO open2026
Insights into rhabdomyosarcoma in the adolescent and young adult population: a comprehensive clinical study from the French Society of Pediatric Oncology (SFCE) Malignant Mesenchymal Tumor (MMT) Committee and the French Sarcoma Group (GSF-GETO).
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005]
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRhabdomyosarcoma (RMS) in adolescent and young adults (AYAs) has a poor prognosis. This study aims to evaluate the prognostic significance of patient, disease, and treatment characteristics, including factors known to impact survival in patients with pediatric RMS, in the AYA population. PATIENTS AND
methodsWe conducted a retrospective review of patients aged 15-25 years treated for RMS in France between 2006 and 2014. Patients were either enrolled in the RMS-2005 study (NCT00379457) or identified through the French databases RRePS, NetSarc, and Conticabase.
resultsA total of 115 patients were included: 64 (56%) aged 15-18 years and 51 (44%) aged 19-25 years. Most patients were male (70%), had a fusion-positive alveolar subtype (51%), lymph node involvement (53%), and metastatic disease (44%). The 5-year overall survival and event-free survival for the entire cohort were 46% [95% confidence interval (CI) 36-55] and 41% (95% CI 32-50), respectively. Multivariate analysis confirmed the prognostic significance of Intergroup Rhabdomyosarcoma Study groups III and IV, analyzed as distinct groups and compared with pooled groups I-II [hazard ratio (HR) 2.21, 95% CI 0.78-6.27 for group III; HR 5.62, 95% CI 2.06-15.33 for group IV; P < 0.001], alveolar subtype (HR 2.50, 95% CI 1.42-4.40, P = 0.002), and the 19-25 years age group (HR 1.85, 95% CI 1.10-3.12, P = 0.02). The care setting (pediatric, AYA, or adult unit) did not significantly impact outcome (P = 0.84). Seventy-seven percent of patients with localized disease had a chemotherapy score of 1 (defined as ≥8 cycles of chemotherapy including an alkylating agent with doxorubicin or d-actinomycin or vincristine), which was associated with improved prognosis (HR 0.25, 95% CI 0.09-0.74, P = 0.012, stratified on propensity score).
conclusionsDespite multimodal treatment, RMS in AYAs has a poorer prognosis than in children, partly due to the higher frequency of unfavorable risk factors. Their inclusion in the ongoing FaR-RMS study (NCT04625907) should lead to a homogenization of their therapeutic management and, ultimately, improve their prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.